Poor
Needs Review
Patient Risk:
Moderate
Summary
Most statements were not verifiable against the provided label text (only limited label sections were supplied). However, at least one substantive claim about an unapproved/contradicted indication (BPD prevention in premature neonates) conflicts with the label text provided.
Category Scores
Accurate Statements
INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.
1 INDICATIONS AND USAGE: "INOmax is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents."
INOmax is contraindicated in neonates dependent on right-to-left shunting of blood.
4 CONTRAINDICATIONS: "INOmax is contraindicated in neonates dependent on right-to-left shunting of blood."
Unsupported Statements
Nitric oxide (Inomax) is used to treat preterm infants with hypoxic respiratory failure by improving oxygenation and reducing pulmonary hypertension.
The provided label text includes efficacy in term and near-term (>34 weeks gestation) neonates; it states that additional studies in premature neonates for BPD prevention have not shown substantial efficacy, but the provided text does not support the specific claim about preterm infants with hypoxic respiratory failure being treated as an indication.
Inomax works by donating nitric oxide to blood vessels, causing them to relax and dilate.
The provided label describes mechanism of action as nitric oxide relaxing vascular smooth muscle (via guanylate cyclase leading to vasodilation) and selective pulmonary vasodilation, but it is not phrased as "donating nitric oxide to blood vessels" in the provided text.
Inomax improves blood flow to the lungs and reduces the risk of respiratory failure.
The label text provided states INOmax increases PaO2 by dilating pulmonary vessels in better ventilated areas and redistributes pulmonary blood flow; it does not explicitly state "reduces the risk of respiratory failure."
Ulspira is not a known or approved product.
The provided label text does not address Ulspira.
There are several products with "Spi" in their name.
The provided label text does not address other product naming.
Spiriva is a prescription medication for chronic obstructive pulmonary disease (COPD).
The provided label text does not address Spiriva.
Spiriva contains tiotropium bromide.
The provided label text does not address Spiriva formulation.
Spiriva does not contain nitrogen oxide.
The provided label text does not address Spiriva composition.
Inomax has been shown to improve oxygenation and reduce pulmonary hypertension in preterm infants with hypoxic respiratory failure.
The label text provided supports term/near-term (>34 weeks gestation) neonates for the stated indication; it does not provide support for a preterm population claim as written.
Inomax was approved by the FDA in 2011 under the Orphan Drug Act.
The provided label text does not include approval year or Orphan Drug Act details.
Under the Orphan Drug Act, Inomax received a seven-year exclusivity period.
The provided label text does not include Orphan Drug exclusivity duration.
Inomax received a five-year pediatric exclusivity period.
The provided label text does not include pediatric exclusivity duration.
Inomax's Orphan Drug Exclusivity expired January 8, 2018.
The provided label text does not include Orphan Drug exclusivity expiration dates.
Inomax's pediatric exclusivity ended January 8, 2019.
The provided label text does not include pediatric exclusivity end dates.
In the United States, marketing exclusivity for Inomax will expire January 8, 2028.
The provided label text does not include marketing exclusivity expiration dates.
Inomax is manufactured by Mallinckrodt Pharmaceuticals.
The provided label text does not include manufacturer information.
Ulspira, as not a valid or approved product, does not have a manufacturer or price listed.
The provided label text does not address Ulspira or manufacturer/price listing.
Contradictions
High
AI Statement
INOmax is indicated to improve oxygenation and reduce the need for ECMO in premature neonates for the prevention of bronchopulmonary dysplasia.
Label Reference
8.4 Pediatric Use: "Additional studies conducted in premature neonates for the prevention of bronchopulmonary dysplasia have not demonstrated substantial evidence of efficacy."
Important Omissions
No prescribing-information evaluation can be fully completed for dosage/administration, boxed warnings, detailed warnings/precautions, adverse reactions, monitoring, administration instructions, and storage/handling because the supplied label excerpts do not include those sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
A key indication-related claim conflicts with the provided label text regarding lack of substantial evidence of efficacy for BPD prevention in premature neonates. Many other statements are unsupported because the relevant label content was not provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Needs Review
Primary Issue
One substantive claim contradicts the provided prescribing information (premature neonatal BPD prevention efficacy). Most other claims are unsupported because the provided label excerpts do not substantiate them (e.g., approval/exclusivity dates, manufacturer, other products).
Suggested Improvement
Limit statements to what is supported by the provided label text (especially indication scope and pediatric/preterm efficacy statements) and remove/qualify claims not present in the supplied label excerpts (e.g., exclusivity/approval dates, manufacturer, other product comparisons).